The Effect of Serum Lithium Levels on Renal Function in Geriatric Outpatients: A Retrospective Longitudinal Study.

Department of Psychiatry, McGill University, Irving Ludmer Research and Training Building, 1033 Pine Avenue West, Montreal, H3A 1A1, Canada, .
Drugs & Aging (Impact Factor: 2.5). 03/2013; 30(6). DOI: 10.1007/s40266-013-0068-x
Source: PubMed

ABSTRACT BACKGROUND: Lithium remains an important treatment for bipolar disorder; however, whether elevated lithium levels lead to long-term renal problems is unknown. Previous consensus opinion was that levels should be kept below 0.6 mmol/L in geriatric patients to minimize renal toxicity. OBJECTIVE: We hypothesized that elevated serum lithium levels correlate with decreased renal function [estimated glomerular filtration rate (eGFR)] in geriatric psychiatry outpatients. STUDY DESIGN: This was a 4-year retrospective cohort study (2007-2011). SETTING: We performed this study in three Canadian university-affiliated tertiary care clinics. PATIENTS: Data from 42 lithium-using geriatric psychiatry outpatients was used. INTERVENTION/EXPOSURE: Our main exposure of interest was mean serum lithium level between 2007 and 2011. MAIN OUTCOME MEASURE: Our primary outcome was change in eGFR between 2007 and 2011 (hypothesis formulated before data collection). RESULTS: Lithium levels did not correlate significantly with change in eGFR at 2- or 4-year follow-up (r < 0.12, p > 0.57). There were no significant predictors of change in eGFR in a multiple linear regression model including hypertension, diabetes, baseline eGFR, lithium duration, and lithium levels. CONCLUSION: Lithium levels do not correlate strongly (ρ > 0.5) with decreased eGFR at 2- and 4-year follow-up in geriatric outpatients. These results are not reliably generalizable when treating patients at mean lithium levels greater than 0.8 mEq/L, especially at 4-year follow-up, and larger studies will be necessary to examine the possibility of a smaller correlation. Nonetheless, these data and the existing literature suggest that lithium levels up to 0.8 mmol/L are safe for use in the long-term treatment of geriatric patients with mood disorders without pre-existing chronic renal failure.

  • [Show abstract] [Hide abstract]
    ABSTRACT: P2C-type ATPases are a subfamily of P-type ATPases comprising Na(+)/K(+)-ATPase and H(+)/K(+)-ATPase. Na(+)/K(+)-ATPase is ubiquitously expressed and has been implicated in several neurological diseases, whereas H(+)/K(+)-ATPase is found principally in the colon, stomach, and kidney. Both ATPases have two subunits, α and β, but Na(+)/K(+)-ATPase also has a regulatory subunit called FXYD, which has an important role in cancer. The most important functions of these ATPases are homeostasis, potassium regulation, and maintaining a gradient in different cell types, like epithelial cells. Na(+)/K(+)-ATPase has become a center of attention ever since it was proposed that it might play a crucial role in neurological disorders such as bipolar disorder, mania, depression, familial hemiplegic migraine, rapid-onset dystonia parkinsonism, chronic stress, epileptogenesis, and Alzheimer's disease. On the other hand, it has been reported that lithium could have a neuroprotective effect against ouabain, which is the best known Na(+)/K(+)-ATPase inhibitor, but and high concentrations of lithium could affect negatively H(+)/K(+)-ATPase activity, that has a key role in regulating acidosis and potassium deficiencies. Finally, potassium homeostasis regulation is composed of two main mechanisms, extrarenal and renal. Extrarenal mechanism controls plasma levels, shifting potassium from the extracellular to the intracellular, whereas renal mechanism concerns with body balance and is influenced by potassium intake and its urinary excretion. In this article, we discuss the functions, isoforms, and localization of P2C-type ATPases, describe some of their modulators, and discuss their implications in some diseases.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lithium is an important medication in the treatment of mood disorders. However, clinicians are hesitant to use lithium in older adults for fear of its medical effects, particularly kidney disease. This review describes the current understanding of the epidemiology and mechanisms underlying chronic kidney disease (CKD) in older lithium users, with recommendations for using lithium safely in late life. Prevalence estimates of CKD in older lithium users range from 42-50 %, which does not differ greatly from the 37.8 % rates seen in community-dwelling non-lithium using, non-psychiatric populations. Clinical and pre-clinical data suggest a variety of synergistic mechanisms contributing to CKD in older lithium users, including aging, cardiovascular factors, oxidative stress, inflammation, nephrogenic diabetes insipidus, acute kidney injury, and medication interactions. With regards to CKD, lithium can be used safely in many older adults with mood disorders. Compared to patients with pre-existing CKD, those with an estimated glomerular filtration rate >60 mL/min/1.73 m(2) are probably not as susceptible to lithium-associated renal decline. Using lithium concentrations <0.8 mmol/L; monitoring lithium concentrations and renal function every 3-6 months; being vigilant about concurrent medication use (e.g., diuretics, anti-inflammatories); as well as preventing/treating acute kidney injury, nephrogenic diabetes insipidus, diabetes mellitus, hypertension, smoking, and coronary artery disease can all help prevent CKD and further renal decline in older lithium users.
    Drugs & Aging 12/2014; 32(1). DOI:10.1007/s40266-014-0234-9 · 2.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lithium is a mainstay of bipolar disorder treatment, however, there are still differences in opinion on the effects of lithium use on renal function. The aim of this analysis was to determine if there is an association between short-term exposure to various elevated lithium levels and estimated-glomerular filtration rate (eGFR) at ≤3 months, 6 months (±3 months) and 1 year (±3 months) follow-up.
    BMJ Open 11/2014; 4(11):e006020. DOI:10.1136/bmjopen-2014-006020 · 2.06 Impact Factor